ArticleCureus2026
When a Transient Ischemic Attack Is Not a Transient Ischemic Attack: Super-refractory Status Epilepticus in GAD65 Antibody-Associated Autoimmune Encephalitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 68-year-old woman with no prior medical history was diagnosed with probable glutamic acid decarboxylase 65 (GAD65) antibody-associated autoimmune encephalitis, which initially mimicked a transient ischemic attack (TIA) before progressing to super-refractory status epilepticus. She initially experienced a transient episode of right-sided weakness and dysarthria, leading to a presumed vascular diagnosis. Eight days later, she returned with right central facial palsy and conduction aphasia, which rapidly progressed to global aphasia and was followed by fever and seizures, prompting neurological reevaluation. Electroencephalography (EEG) demonstrated encephalopathic activity with epileptiform discharges, while cerebrospinal fluid (CSF) analysis revealed isolated protein elevation without pleocytosis. Extensive investigations for infectious, neoplastic, neurodegenerative, and systemic autoimmune causes were unrevealing. Brain fluorodeoxyglucose-PET/CT (FDG PET/CT) demonstrated diffuse cortical hypermetabolism, a finding compatible with autoimmune encephalitis but one that may also have been influenced by ongoing or recent ictal activity. Given the high suspicion for autoimmune status epilepticus, empiric treatment with methylprednisolone and intravenous immunoglobulin (IVIG) was initiated before the results of CSF autoimmune antibody testing became available. The patient subsequently demonstrated progressive clinical and electrographic improvement. After a prolonged ICU stay, she recovered with minimal disability. Follow-up serum testing revealed low-titer anti-GAD65 antibodies, which supported the diagnosis despite negative CSF autoimmune antibody testing. This report highlights the diagnostic challenges of GAD65 antibody-associated encephalitis presenting with cerebrovascular-like episodes, the potential discordance between serum and CSF antibody testing, and the importance of early empiric immunotherapy in suspected autoimmune encephalitis, even when initial diagnostic studies remain inconclusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.